It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The osteoblast differentiation capacity of skeletal stem cells (SSCs) must be tightly regulated, as inadequate bone formation results in low bone mass and skeletal fragility, and over-exuberant osteogenesis results in heterotopic ossification (HO) of soft tissues. RUNX2 is essential for tuning this balance, but the mechanisms of posttranslational control of RUNX2 remain to be fully elucidated. Here, we identify that a CK2/HAUSP pathway is a key regulator of RUNX2 stability, as Casein kinase 2 (CK2) phosphorylates RUNX2, recruiting the deubiquitinase herpesvirus-associated ubiquitin-specific protease (HAUSP), which stabilizes RUNX2 by diverting it away from ubiquitin-dependent proteasomal degradation. This pathway is important for both the commitment of SSCs to osteoprogenitors and their subsequent maturation. This CK2/HAUSP/RUNX2 pathway is also necessary for HO, as its inhibition blocked HO in multiple models. Collectively, active deubiquitination of RUNX2 is required for bone formation and this CK2/HAUSP deubiquitination pathway offers therapeutic opportunities for disorders of inappropriate mineralization.
Runx2 is essential for tuning the generation of bone from skeletal stem cells (SSCs). Here, the authors demonstrate that the CK2/HAUSP pathway stabilizes RUNX2 protein thereby regulating the commitment of SSCs to osteoprogenitors as well as their subsequent maturation, and that inhibition of this pathway can block heterotopic ossification.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Massachusetts Medical School, Department of Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
2 Yonsei University College of Medicine, Department of Orthopaedic Surgery, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
3 Xiamen University, State Key Laboratory of Cellular Stress Biology, Fujian, China (GRID:grid.12955.3a) (ISNI:0000 0001 2264 7233)
4 Sungkyunkwan University, Department of integrative biotechnology, Suwon, South Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X)
5 Korea Advanced Institute of Science and Technology, Department of Mathematical Sciences, Daejeon, South Korea (GRID:grid.37172.30) (ISNI:0000 0001 2292 0500)
6 Weill Cornell Medical College, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
7 Brigham and Women’s Hospital, Harvard Medical School, Department of Orthopedics and Medicine, Boston, USA (GRID:grid.5386.8)
8 Commissariat à l’Énergie Atomique et aux Énerigies Alternatives Grenoble, INSERM U1036, pour le Vivant/Biologie du Cancer et de l’Infection, Grenoble, France (GRID:grid.457348.9)
9 KinaseDetect ApS, Krusaa, Denmark (GRID:grid.457348.9)
10 Brigham and Women’s Hospital, Harvard Medical School, Division of Cardiovascular Medicine, Department of Medicine, Boston, USA (GRID:grid.457348.9)
11 Institute of Cancer Genetics, College of Physicians and Surgeons of Columbia University, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
12 Institute of Cancer Genetics, College of Physicians and Surgeons of Columbia University, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); College of Physicians and Surgeons of Columbia University, Department of Pathology and Cell Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
13 Okayama University Graduate School of Medicine, Department of Regenerative Science, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
14 University of Massachusetts Medical School, Department of Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Li Weibo Institute for Rare Diseases Research, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)